Valentina De Falco

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6689164/publications.pdf

Version: 2024-02-01

34 papers	2,142 citations	236925 25 h-index	361022 35 g-index
35 all docs	35 docs citations	35 times ranked	2733 citing authors

#	Article	IF	Citations
1	Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes and Diseases, 2023, 10, 1367-1401.	3.4	152
2	The Role of Nutrients in Prevention, Treatment and Post-Coronavirus Disease-2019 (COVID-19). Nutrients, 2022, 14, 1000.	4.1	12
3	Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene. Journal of Experimental and Clinical Cancer Research, 2018, 37, 84.	8.6	20
4	The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 307-318.	4.7	26
5	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2016, 126, 1603-1603.	8.2	111
6	Fragmentâ€Based Discovery of a Dual panâ€RET/VEGFR2 Kinase Inhibitor Optimized for Singleâ€Agent Polypharmacology. Angewandte Chemie - International Edition, 2015, 54, 8717-8721.	13.8	33
7	Calcium/Calmodulin-Dependent Protein Kinase II and Its Endogenous Inhibitor Î± in Medullary Thyroid Cancer. Clinical Cancer Research, 2014, 20, 1513-1520.	7.0	18
8	Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. American Journal of Physiology - Renal Physiology, 2014, 306, F1243-F1250.	2.7	16
9	Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E811-E819.	3.6	77
10	CD44 Proteolysis Increases CREB Phosphorylation and Sustains Proliferation of Thyroid Cancer Cells. Cancer Research, 2012, 72, 1449-1458.	0.9	58
11	XB130 Mediates Cancer Cell Proliferation and Survival through Multiple Signaling Events Downstream of Akt. PLoS ONE, 2012, 7, e43646.	2.5	36
12	Mitochondrial Localization and Regulation of BRAFV600E in Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAFV600E. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E19-E30.	3.6	51
13	Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors inBRAFMutant Thyroid Carcinoma Cells. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 450-455.	3.6	90
14	The Ca2+â€“calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC. Endocrine-Related Cancer, 2010, 17, 113-123.	3.1	21
15	The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocrine-Related Cancer, 2010, 18, 1-11.	3.1	58
16	The Î²-Catenin Axis Integrates Multiple Signals Downstream from RET/Papillary Thyroid Carcinoma Leading to Cell Proliferation. Cancer Research, 2009, 69, 1867-1876.	0.9	82
17	Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. Journal of Molecular Endocrinology, 2009, 43, 143-155.	2.5	74
18	Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 1634-1645.	4.1	26

#	Article	IF	Citations
19	XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. Oncogene, 2009, 28, 937-949.	5.9	59
20	Functional Characterization of the Novel T599I-VKSRdel BRAF Mutation in a Follicular Variant Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4398-4402.	3.6	32
21	Cytosolic Phospholipase A2Î± Regulates Cell Growth in RET/PTC-Transformed Thyroid Cells. Cancer Research, 2007, 67, 11769-11778.	0.9	13
22	RET/Papillary Thyroid Carcinoma Oncogenic Signaling through the Rap1 Small GTPase. Cancer Research, 2007, 67, 381-390.	0.9	50
23	Biological Role and Potential Therapeutic Targeting of the Chemokine Receptor CXCR4 in Undifferentiated Thyroid Cancer. Cancer Research, 2007, 67, 11821-11829.	0.9	100
24	Biochemical and molecular characterization of the novel BRAFV599Ins mutation detected in a classic papillary thyroid carcinoma. Oncogene, 2006, 25, 4235-4240.	5.9	56
25	A novel pathway of cell growth regulation mediated by a PLA 2 Î±â€derived phosphoinositide metabolite. FASEB Journal, 2006, 20, 2567-2569.	0.5	32
26	BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma. Clinical Cancer Research, 2006, 12, 1623-1629.	7.0	160
27	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2005, 115, 1068-1081.	8.2	231
28	RAI(ShcC/N-Shc)-dependent recruitment of GAB1 to RET oncoproteins potentiates PI3-K signalling in thyroid tumors. Oncogene, 2005, 24, 6303-6313.	5.9	30
29	Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5270-5278.	3.6	71
30	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2005, 115, 1068-1081.	8.2	126
31	A New Germline RET Mutation Apparently Devoid of Transforming Activity Serendipitously Discovered in a Patient with Atrophic Autoimmune Thyroiditis and Primary Ovarian Failure. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4810-4816.	3.6	18
32	Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene, 2004, 23, 5958-5967.	5.9	119
33	The Oncogenic Activity of RET Point Mutants for Follicular Thyroid Cells May Account for the Occurrence of Papillary Thyroid Carcinoma in Patients Affected by Familial Medullary Thyroid Carcinoma. American Journal of Pathology, 2004, 165, 511-521.	3.8	35
34	Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene, 2003, 22, 246-255.	5.9	46